StreetInsider.com News Articles

Selloff in this major biotech stock is "overdone," BTIG says

Tue, 02 Jun 2026 11:00:00 -0400

A sharp pullback in a clinical-stage biotechnology company following its Phase 3 trial readout is unwarranted, BTIG analysts say.

Shares in French biotech firm Abivax (NASDAQ: ABVX) fell sharply on Tuesday despite its experimental ulcerative colitis (UC) pill posting stronger-than-expected late-stage trial results, as the headline numbers were overshadowed by the emergence of rare malignancy events in the data.

The company's Paris-listed shares sank more than 38% in European trading.

However, BTIG analyst Julian Harrison argues that the drug's efficacy results represent the strongest maintenance data seen in ulcerative colitis to date and that a small number of cancer cases flagged by investors

Selloff in this major biotech stock is "overdone," BTIG says

Tue, 02 Jun 2026 11:00:00 -0400

A sharp pullback in a clinical-stage biotechnology company following its Phase 3 trial readout is unwarranted, BTIG analysts say.

The company's Paris-listed shares sank more than 38% in European trading.

Abivax (ABVX) PT Lowered to $135 at Truist Securities

Tue, 02 Jun 2026 08:57:23 -0400

(Updated - June 2, 2026 8:57 AM EDT)

Truist Securities analyst Greg Renza lowered the price target on Abivax (NASDAQ: ABVX) to $135.00 (from $140.00) while maintaining a Buy rating.

The analyst commented: "Ph.III Maintenance Efficacy Impresses with 39%+ CR, Safety on Watch; We Anticipate Vol' Into 4Q NDA Filing; After the close today, ABVX reported topline maintenance data from the ph.III ABTECT study for obefazimod (obe'), which showed 39.3% and 40.3% placebo-adjusted clinical remission at wk 44 in the 25mg and 50mg cohorts, respectively. Into the data, we set a 30% placebo-adjusted response as our bar, with today's efficacy a best

Abivax (ABVX) PT Lowered to $135 at Truist Securities

Tue, 02 Jun 2026 08:57:23 -0400

(Updated - June 2, 2026 8:57 AM EDT)

Truist Securities analyst Greg Renza lowered the price target on Abivax (NASDAQ: ABVX) to $135.00 (from $140.00) while maintaining a Buy rating.

Abivax (ABVX) PT Lowered to $132 at Morgan Stanley

Tue, 02 Jun 2026 07:50:27 -0400

Morgan Stanley analyst Judah Frommer lowered the price target on Abivax (NASDAQ: ABVX) to $132.00 (from $145.00) while maintaining a Overweight rating.

Wedbush Upgrades Abivax (ABVX) to Neutral

Tue, 02 Jun 2026 07:37:06 -0400

(Updated - June 2, 2026 7:37 AM EDT)

Wedbush analyst David Nierengarten upgraded Abivax (NASDAQ: ABVX) from Underperform to Neutral, PT $90.00 (from $110.00).

The analyst comments "ABVX reported placebo-adjusted maintenance clinical remission rates of ~40%, above our benchmark expectations of 20-30%, but disclosed malignancies at the higher dose of 50 mg QD. In the 50 mg cohort, 7 malignancies (3 excluding nonmelanoma skin cancer) occurred, compared to 1 each in the 25 mg and placebo cohorts. We view these signals as increasing risk for an eventual black box warning, and prior to approval, an FDA AdComm, especially considering the novel proposed

Wedbush Upgrades Abivax (ABVX) to Neutral

Tue, 02 Jun 2026 07:37:06 -0400

(Updated - June 2, 2026 7:37 AM EDT)

Wedbush analyst David Nierengarten upgraded Abivax (NASDAQ: ABVX) from Underperform to Neutral, PT $90.00 (from $110.00).

Abivax stock sinks 32% as rare malignancy events cloud solid colitis trial data

Tue, 02 Jun 2026 06:09:51 -0400

Investing.com -- Abivax shares plunged on Tuesday after its experimental ulcerative colitis pill posted stronger-than-expected late-stage trial results, but the headline numbers were overshadowed as the data flagged rare malignancy events.

The company’s Paris-listed shares sank more than 32% in early European trading by 07:34 GMT.

In the 44-week study, roughly half of patients on both doses of the oral drug, obefazimod, achieved clinical remission — 50.8% on the 25 milligram dose and 51.3% on the 50 milligram dose — compared with 10.4% of those on placebo. The results came in well above expectations and appeared to outperform existing therapies.

Obefazimod was broadly well

Form 6-K Abivax S.A. For: Jun 01

Tue, 02 Jun 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260602/26586824.html

Form 6-K Abivax S.A. For: Jun 01

Tue, 02 Jun 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260602/26586824.html

Form 6-K Abivax S.A. For: Jun 01

Tue, 02 Jun 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260602/26586824.html

Abivax (ABVX) PT Raised to $187 at Citizens

Tue, 02 Jun 2026 04:04:23 -0400

Citizens analyst Jason Butler raised the price target on Abivax (NASDAQ: ABVX) to $187.00 (from $131.00) while maintaining a Market Outperform rating.

The analyst comments: “Phase 3 maintenance results support that obefazimod can be paradigm changing for the treatment of ulcerative colitis; we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target from $131 to $187. Yesterday afternoon, Abivax announced positive top-line results from the Phase 3 ABTECT maintenance trial with clinical remission rates substantially exceeding our and Street expectations. We view efficacy (~40% placebo-adjusted clinical remission rate) as best in indication, easily surpassing drugs across all approved

Abivax (ABVX) PT Raised to $187 at Citizens

Tue, 02 Jun 2026 04:04:23 -0400

Citizens analyst Jason Butler raised the price target on Abivax (NASDAQ: ABVX) to $187.00 (from $131.00) while maintaining a Market Outperform rating.

Jefferies Downgrades Abivax (ABVX) to Hold

Tue, 02 Jun 2026 01:03:29 -0400

Jefferies analyst Faisal Khurshid downgraded Abivax (NASDAQ: ABVX) from Buy to Hold with a price target of $90.00 (from $160.00).

The analyst comments: “Key catalyst ABTECT UC maintenance showed BIC efficacy, but cancer signal complicates matters. Even if unrelated noise, we think the overhang will be real, especially considering absence of other value-inflecting data events over the next yr. Key debates unlikely to have an answer soon: (1) cause/relatedness of cancer events, (2) impact on strategic optionality, and (3) approval risk (AdCom, black box, etc). Path to upside hard to envision and we d/g to HOLD.

ABVX is developing obefazimod (miR-124) in

Jefferies Downgrades Abivax (ABVX) to Hold

Tue, 02 Jun 2026 01:03:29 -0400

Jefferies analyst Faisal Khurshid downgraded Abivax (NASDAQ: ABVX) from Buy to Hold with a price target of $90.00 (from $160.00).

ABVX is developing obefazimod (miR-124) in

After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP

Mon, 01 Jun 2026 16:37:47 -0400

After-Hours Stock Movers

Hewlett Packard Enterprise (NYSE: HPE)

Hewlett Packard Enterprise skyrocketed 35% after hours, building on a 9% intraday gain, after posting a massive Q2 beat with an EPS of $0.79 and revenue of $10.7 billion. The stock's surge was further fueled by significantly raised Q3 and full-year fiscal 2026 guidance, easily clearing Wall Street expectations across the board.